Home › Funds › APIS CAPITAL ADVISORS, LLC › SNDX
APIS CAPITAL ADVISORS, LLC position in SNDX
SYNDAX PHARMACEUTICALS INC · Health Care
APIS CAPITAL ADVISORS, LLC reported holding 605,000 shares of SNDX (SYNDAX PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$11.4M, representing 1.61% of its reported portfolio and ranking #21 among its reported holdings. APIS CAPITAL ADVISORS, LLC has disclosed SNDX holdings in 5 of the last 5 reported quarters, going back to Q3 2025.
Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR
How APIS CAPITAL ADVISORS, LLC's SNDX position evolved
APIS CAPITAL ADVISORS, LLC first disclosed a stake in SNDX in Q3 2025 at 638,000 shares (US$9.8M). The position peaked in Q4 2025 at 724,000 shares, worth US$15.2M. Across 5 filings, APIS CAPITAL ADVISORS, LLC increased the stake 3 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 605,000 shares valued at US$11.4M — an increase of 49,000 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2025 | 638.00K | $9.82M | New |
| Q4 2025 | 724.00K | $15.21M | Add |
| Q1 2026 | 550.00K | $12.85M | Reduce |
| Q2 2026 | 556.00K | $12.15M | Add |
| Q3 2026 | 605.00K | $11.37M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About SNDX and 13F data
SNDX (SYNDAX PHARMACEUTICALS INC) is a Health Care company. 38 other funds we track also report a position in SNDX — the largest reported positions include Kynam Capital Management, LP (US$176.0M), DEERFIELD MANAGEMENT COMPANY, L.P. (US$82.6M), Eversept Partners, LP (US$61.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding SNDX
- Kynam Capital Management, LP 8.05M sh · $175.99M · Q2 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 3.78M sh · $82.63M · Q2 2026
- Eversept Partners, LP 2.80M sh · $61.17M · Q2 2026
- KINGDON CAPITAL MANAGEMENT, L.L.C. 2.50M sh · $54.65M · Q2 2026
- Elmind Capital, LP 1.85M sh · $40.55M · Q2 2026
- Soleus Capital Management, L.P. 1.63M sh · $35.59M · Q2 2026
- ORBIMED ADVISORS LLC 1.54M sh · $33.71M · Q2 2026
- MPM BioImpact LLC 1.33M sh · $29.15M · Q2 2026
- Catalio Capital Management, LP 1.22M sh · $26.58M · Q2 2026
- Aisling Capital Management LP 1.32M sh · $24.76M · Q3 2026
- Trails Edge Capital Partners, LP 1.11M sh · $24.26M · Q2 2026
- SPHERA FUNDS MANAGEMENT LTD. 1.01M sh · $22.18M · Q2 2026
More on APIS CAPITAL ADVISORS, LLC
FAQ
How long has APIS CAPITAL ADVISORS, LLC held SNDX?
APIS CAPITAL ADVISORS, LLC has disclosed SNDX holdings in 5 of the last 5 reported quarters, going back to Q3 2025.
What is APIS CAPITAL ADVISORS, LLC's current position in SNDX?
As of Q3 2026, APIS CAPITAL ADVISORS, LLC holds 605.00K shares of SNDX (SYNDAX PHARMACEUTICALS INC), valued at $11.37M, representing 1.61% of its reported portfolio and ranking #21.
Has APIS CAPITAL ADVISORS, LLC been buying or selling SNDX?
In the latest 13F filing (Q3 2026), APIS CAPITAL ADVISORS, LLC increased its position in SNDX. The position peaked in Q4 2025 at 724.00K shares.
Which other funds hold SNDX?
Other major institutional holders of SNDX include Kynam Capital Management, LP, DEERFIELD MANAGEMENT COMPANY, L.P., Eversept Partners, LP, among 38 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.